XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
3 Months Ended
Jul. 30, 2013
Mar. 31, 2025
Mar. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue   $ 2,739 $ 25,364
AstraZeneca Agreements [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue   36,900 $ 27,100
AstraZeneca Agreements [Member] | U.S./RoW [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Aggregate considerations received   439,000  
AstraZeneca Agreements [Member] | China [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Upfront, non-contingent, non-refundable and time-based payments $ 376,700    
Aggregate considerations received   $ 81,200